OncoGenex Pharmaceuticals Inc. to Present at Upcoming Investor Conference
Published: Nov 09, 2012
BOTHELL, WA and VANCOUVER, BC, Nov. 9, 2012 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 14, 2012 at 10:00 a.m. ET at the Pierre Hotel in New York City.
Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. Webcast replays will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com
SOURCE OncoGenex Pharmaceuticals, Inc.